Human full-length and Δ3-22 CYP3A4, as well as the R212A and T224A variants were produced as reported previously (21 (link), 39 (link)). The F219A mutation was introduced using PrimeSTAR Max DNA Polymerase master mix (Takara Bio) and confirmed by sequencing. The F219A variant of Δ3-22 CYP3A4 was expressed and purified using the protocol developed for WT CYP3A4 (39 (link)). All proteins used in the study had Rz (A416/280 nm ratio) of 1.5 or higher.
Free full text: Click here